



E-mail: queries@zenlabsethica.com, Website : www.zenlabsethica.com


Date: 3rd, November, 2021

Ref: Zenlabs Ethica Limited Scrip Code: 530697

The details of the same is as under:

This being an inter-se transfer of shares amongst promoter and Promoter Group, the same falls within the exemption under Regulation 10(1)(a)(ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (qualifying person being persons named as promoters in the shareholding pattern filed by the target company for not less than 15% of the total shareholding).

1. The first step in the process of identifying a problem is to recognize that a problem exists. This is often done by comparing current performance with a desired state or goal. If there is a discrepancy, a problem is identified.



H W H



Preet Remedies Limited

Regd. Office : Plot No. 194-195 (3rd Floor), Industrial Area, Phase-II, Chandigarh-160 002

Tel. : 0172-4651105, 3920738, Fax : 0172-2656855, E-mail : preetremedies@gmail.com

CIN No. U24230CH2005PLC27954

Ref. No.....

Dated.....

Date: 3rd, November, 2021

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers

Dalal Street, Mumbai-400001

Maharashtra

Sub: Prior intimation under Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the proposed acquisition of shares

Dear Sir/Ma'am,

In due compliance of Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, the undersigned being part of the promoter and promoter group, hereby furnish the prior intimation in the specified format under Regulation 10(5) in respect of proposed inter-se transfer of 6,77,957 (10.41%) equity shares of Zenlabs Ethica Limited being the Target Company ("TC") from Sh. Harpreet Singh Kalra to M/s Preet Remedies Limited, being promoters of TC;

The above proposed acquisitions shall qualify as "Inter-se transfer" under Reg. 10(1)(a)(ii) of SEBI, (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and there will be no change in the aggregate shareholding of the Promoter Group.

Kindly take the same on record and suitably disseminate to all concerned.

Thanking You

For Preet Remedies Limited

Sanjay Dhir
Director

Place: Chandigarh

Date: 03/11/2021



Preet Remedies

Preet Remedies Limited

Regd. Office : Plot No. 194-195, Industrial Area, Phase-II, Chandigarh-160 002

Tel. : 0172-4651503, 3920735, Fax : 0172-4656655, E-mail : preetremedies@gmail.com

CIN No. U24230CH2005PLC27954

Ref. No.....

Dated.....

Disclosures under Regulation 10(5) – Intimation to Stock Exchanges in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Zenlabs Ethica Limited
2.	Name of the acquirer(s)	Preet Remedies Limited CIN: U24230CH2005PLC027954
3.	Whether the acquirer(s) is/are associated with the Target Company	

5.	Relevant sub-clause of regulation 10(1)(a) under which the acquirer is exempted from making open offer	Regulation 10(1)(a)(ii) of the Securities And Exchange Board of India (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011
----	--	---


6.	If frequently traded, volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice as traded on the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period.	The shares of the target company are frequently traded in terms of Regulation 2(1)(j) of the SEBI (SAST) Regulations, 2011. The volume-weighted average market price for a period of sixty trading days preceding the date of issuance of this notice, as traded on the stock exchange where the maximum volume of trading in the shares of the target company are recorded during such period is Rs. 35.42 Per share.
7.	If in-frequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	Not Applicable

8.	Declaration by the acquirer, that the acquisition price would not be higher by more than 25% of the price computed in point 6 or point 7 as applicable.	Attached as Annexure I
----	---	------------------------

9.	Declaration by the acquirer, that the transferor and transferee have complied / will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997)	Attached as Annexure II
----	---	-------------------------

10.	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with.	Attached as Annexure III
-----	---	--------------------------

11.	Shareholding details	Before the proposed transaction		After the proposed transaction	
		No. of shares /voting rights	% w.r.t total share capital of TC	No. of shares /voting rights	% w.r.t total share capital of TC
a	Acquirer(s) and PACs (other than sellers)(*)				
	PREET REMEDIES LIMITED	20,04,003	30.78	26,81,960	41.20



Total : Acquirer(s) and PACs (other than sellers)		20,04,003	30.78	26,81,960	41.20
b	Seller (s)				
	Mr. HARPREET SINGH KALRA	6,77,957	10.41	Nil	Nil
Total : Seller (s)		6,77,957	10.41	Nil	Nil

Note:

- (*) Shareholding of each entity may be shown separately and then collectively in a group.
- The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirer.

For Preet Remedies Limited
Acquirer

Sanjay Dhir
Sanjay Dhir
Director



Place: Chandigarh
Date: 03/11/2021



Preet Remedies

Preet Remedies Limited

Regd. Office : Plot No. 194-195 (3rd Floor), Industrial Area, Phase-II, Chandigarh-160 002
Tel. : 0172-4651105, 3920738, Fax : 0172-2656855, E-mail : preetremedies@gmail.com
CIN No. U24230CH-2008PLC27956

Dated: _____

Ref. No. _____





Preet Remedies Limited

Regd. Office : Plot No. 194-195 (3rd Floor), Industrial Area, Phase-II, Chandigarh-160 002
Tel. : 0172-4651105, 3920738, Fax : 0172-2656855, E-mail : preetremedies@gmail.com
CIN No. U24230CH2005PLC27954

Ref. No.....

Dated.....

ANNEXURE II

DECLARATION

I Sanjay Dhir S/o Sh. Amar Nath Dhir on behalf of Preet Remedies Limited, promoter and Acquirer of Zenlabs Ethica Limited ("TC"), hereby declare, that the transferor and transferee have complied/will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997),

**For Preet Remedies Limited
Acquirer**

**Sanjay Dhir
Director**

**House No.-1042 Sector-36C,
Chandigarh-160036, India**



**Place: Chandigarh
Date: 03/11/2021**



Preet Remedies Limited

Regd. Office : Plot No. 194-195 (3rd Floor), Industrial Area, Phase-II, Chandigarh-160 002

Tel. : 0172-2651105, 2651738, Fax : 0172-2656855, E-mail : preetremedies@gmail.com

CIN No. U24230CH2005PLC27954

Ref No.....

Dated.....

TO THE MEMBER,

THE COMPANY HAS THE HONOR TO INFORM YOU THAT THE ANNUAL GENERAL MEETING OF THE MEMBERS OF THE COMPANY WILL BE HELD ON 15th MAY 2016 AT 11:00 AM AT THE REGD. OFFICE OF THE COMPANY, PLOT NO. 194-195 (3RD FLOOR), INDUSTRIAL AREA, PHASE-II, CHANDIGARH-160 002.

Jai Shri

